Drugs / CAR2219-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06834529 | Jan 2025 → Jan 2027 expected | B-cell neoplasm | Affiliated Hospital to Academy of Military Medical Sciences | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR2219-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06834529 ↗ |
| Known as | CAR2219 CAR-T cells | “This is a single arm study to evaluate the safety and efficacy of CAR2219 CAR-T cells in the treatment of relapsed/refractory CD19/CD22 positive B cell Leukemia and Lymphoma.” NCT06834529 ↗ |
| Modality | Cell therapy | “CAR2219 CAR-T cells” NCT06834529 ↗ |
| Route | Intravenous | “Route of administration: Intravenous injection” NCT06834529 ↗ |
| Target | CD19 | “anti-CD19 and anti-CD22 dual specific CAR-T Cells” NCT06834529 ↗ |
| Target | CD22 | “anti-CD19 and anti-CD22 dual specific CAR-T Cells” NCT06834529 ↗ |